朱雄,药物化学博士,suncitygroup太阳集团研究员,博士生导师,医药化工研究所所长。兼任世界中联儿童医药健康产品产业会常务理事,世界中联经皮给药委员会常务理事等。南京领军型科技创业企业家,南京“创新型企业家培育计划”人才。
近年来主要从事创新性小分子药物研究开发工作,先后主持承担各类科研项目数十项,包括国家“重大新药创制”科技重大专项2项、江苏省、福建省科技重大项目数项和多项横向开发项目,具有新药研发及产业化三十余年经验,为社会创造了数十亿的产值。获得国家各类新药证书15本,新药临床批件13件;申请国内外发明专利20余项,在国内外核心刊物上发表论文30余篇。开发的国家1.1类创新药去氧鬼臼毒素目前处于I期临床研究阶段,已成功进行商业化授权,该工作于2020年获评2019年度江苏省科学技术一等奖。
研究方向:
1. 抗菌药物、抗糖尿病药物、心脑血管药物和抗肿瘤药物的设计与合成研究;
2. 候选化合物的成药性评价;
3. 国外上市新药的创新工艺研究。
联系方式:025-83355763 Email:cpuzx@foxmail.com
近期5篇代表性论文:
1. Shangde Liu, Duo Yuan, Shanshan Li, Roujie Xie, Yi Kong, Xiong Zhu*. Synthesis and evaluation of novel and potent protease activated receptor 4 (PAR4) antagonists based on a quinazolin-4(3H)-one scaffold. European Journal of Medicinal Chemistry, 2021, 225, 113764.
2. Shangde Liu, Shanshan Li, Duo Yuan, Enmao Wang, Roujie Xie, Weiqi Zhang, Yi Kong, Xiong Zhu*.Protease activated receptor 4 (PAR4) antagonists: Research progress on small molecules in the field of antiplatelet agents. European Journal of Medicinal Chemistry, 2021, 209, 112893.
3. Qiyang Yin, Bo Zhao, Jianping Zhu, Yuxiang Fei, Weiyang Shen, Bingwen Liang, Xiong Zhu*, Yuman Li*. JLX001 improves myocardial ischemia-reperfusion injury by activating Jak2-Stat3 pathway. Life Sciences, 2020, 257, 118083.
4. Bo Zhao, Jianping Zhu, Yuxiang Fei, Qiyang Yin, Weiyang Shen, Bingwen Liang, Xiong Zhu*, Yunman Li*. JLX001 attenuates blood-brain barrier dysfunction in MCAO/R rats via activating the Wnt/β-catenin signaling pathway. Life Sciences, 2020, 260, 118221.
5. Luyao Ao, Wanting Li, Lin Zhou, Yunyi Yan, An-qi Ye, Bing-wen Liang, Wei-yang Shen, Xiong Zhu*, Yun-man Li*. Therapeutic effects of JLX-001 on ischemic stroke by inducing autophagy via AMPK-ULK1 signaling pathway in rats. Brain Research Bulletin, 2019, 153, 162-170.